We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Catalyst (CPRX) Reports Narrower-than-Expected Loss in Q4
Read MoreHide Full Article
Catalyst Pharmaceuticals, Inc. (CPRX - Free Report) reported a loss of 5 cents per share in the fourth quarter of 2016, a penny narrower than the Zacks Consensus Estimate and also narrower than the loss of 7 cents in the year-ago quarter.
Being a development-stage company, Catalyst Pharma does not have any approved product in its portfolio yet.
Catalyst Pharma’s share price has increased 47.6% year to date, while the Zacks classified Medical-Drugs industry gained 3.9%.
Quarter in Detail
Research and development (R&D) expenses were $2.8 million, down 26.4% from the year-ago quarter.The decline was due to continued activities related to ongoing studies and trials for Firdapse, including the costs of Firdapse Expanded Access Program, and cost of the company’s CPP-115 and generic Sabril programs.
General and administrative expenses were down 36.7% to $1.5 million. The was primarily due to the company’s efforts to conserve cash after the receipt of the FDA’s “refusal to file letter” for Firdapse.
2016 Results
For full-year 2016, the company reported a loss of 22 cents per share compared with loss of 25 cents in 2015. This loss was narrower than the Zacks Consensus Estimate loss of 23 cents.
Pipeline Update
Given that Catalyst Pharma does not have any revenue-generating product in its portfolio yet, investors are expected to focus on pipeline and regulatory updates. At present, Catalyst Pharma has two candidates under development – Firdapse and CPP-115.
In late Oct 2016, the company reached an agreement with the FDA for a Special Protocol Assessment for the design, clinical endpoints, and statistical analysis of the upcoming second phase III study on its lead pipeline candidate, Firdapse, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS). The company began enrolling patients into second phase III study to evaluate the efficacy and safety of Firdapse in patients with LEMS.
Additionally, Catalyst Pharma expanded congenital myasthenic syndromes (CMS) trial on Firdapse beyond pediatric patients to include adult CMS patients and increase patient enrollment size.
The company also expects top-line results from LEMS and CMS trials and plans to submit an NDA for Firdapse in second half of 2017. Moreover, the company anticipates reinitiating pre-commercialization activities for a potential launch of Firdapse in 2018.
Furthure, Catalyst Pharma is working on developing a generic version of Sabril (vigabatrin). The company is also exploring alternatives for further development of CPP-115.
Catalyst Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Catalyst Pharma currently has a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include include Heska Corporation , Retrophin, Inc. and Addus HomeCare Corporation (ADUS - Free Report) . While Heska and Retrophin carry a Zacks Rank #1 (Strong Buy), Addus HomeCare carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Heska’s earnings estimates increased from $1.53 to $1.65 for 2017 and from $1.90 to $2.01 for 2018, over the last 30 days. The company posted a positive earnings surprise in all of the four trailing quarters with an average beat of 291.54%. Its share price increased 34.3% year to date.
Retrophin’s loss estimates narrowed from 85 cents to 72 cents for 2017 and from 67 cents to 53 cents for 2018, over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 80.55%. Its share price increased 1.7% year to date.
Addus HomeCare’s earnings estimates increased from $1.38 to $1.41 for 2017 over the last 60 days. The company posted a positive earnings surprise in two of the four trailing quarters with an average beat of 10.14%.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Catalyst (CPRX) Reports Narrower-than-Expected Loss in Q4
Catalyst Pharmaceuticals, Inc. (CPRX - Free Report) reported a loss of 5 cents per share in the fourth quarter of 2016, a penny narrower than the Zacks Consensus Estimate and also narrower than the loss of 7 cents in the year-ago quarter.
Being a development-stage company, Catalyst Pharma does not have any approved product in its portfolio yet.
Catalyst Pharma’s share price has increased 47.6% year to date, while the Zacks classified Medical-Drugs industry gained 3.9%.
Quarter in Detail
Research and development (R&D) expenses were $2.8 million, down 26.4% from the year-ago quarter.The decline was due to continued activities related to ongoing studies and trials for Firdapse, including the costs of Firdapse Expanded Access Program, and cost of the company’s CPP-115 and generic Sabril programs.
General and administrative expenses were down 36.7% to $1.5 million. The was primarily due to the company’s efforts to conserve cash after the receipt of the FDA’s “refusal to file letter” for Firdapse.
2016 Results
For full-year 2016, the company reported a loss of 22 cents per share compared with loss of 25 cents in 2015. This loss was narrower than the Zacks Consensus Estimate loss of 23 cents.
Pipeline Update
Given that Catalyst Pharma does not have any revenue-generating product in its portfolio yet, investors are expected to focus on pipeline and regulatory updates. At present, Catalyst Pharma has two candidates under development – Firdapse and CPP-115.
In late Oct 2016, the company reached an agreement with the FDA for a Special Protocol Assessment for the design, clinical endpoints, and statistical analysis of the upcoming second phase III study on its lead pipeline candidate, Firdapse, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS). The company began enrolling patients into second phase III study to evaluate the efficacy and safety of Firdapse in patients with LEMS.
Additionally, Catalyst Pharma expanded congenital myasthenic syndromes (CMS) trial on Firdapse beyond pediatric patients to include adult CMS patients and increase patient enrollment size.
The company also expects top-line results from LEMS and CMS trials and plans to submit an NDA for Firdapse in second half of 2017. Moreover, the company anticipates reinitiating pre-commercialization activities for a potential launch of Firdapse in 2018.
Furthure, Catalyst Pharma is working on developing a generic version of Sabril (vigabatrin). The company is also exploring alternatives for further development of CPP-115.
Catalyst Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Catalyst Pharmaceuticals, Inc. Price, Consensus and EPS Surprise | Catalyst Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Catalyst Pharma currently has a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include include Heska Corporation , Retrophin, Inc. and Addus HomeCare Corporation (ADUS - Free Report) . While Heska and Retrophin carry a Zacks Rank #1 (Strong Buy), Addus HomeCare carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Heska’s earnings estimates increased from $1.53 to $1.65 for 2017 and from $1.90 to $2.01 for 2018, over the last 30 days. The company posted a positive earnings surprise in all of the four trailing quarters with an average beat of 291.54%. Its share price increased 34.3% year to date.
Retrophin’s loss estimates narrowed from 85 cents to 72 cents for 2017 and from 67 cents to 53 cents for 2018, over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 80.55%. Its share price increased 1.7% year to date.
Addus HomeCare’s earnings estimates increased from $1.38 to $1.41 for 2017 over the last 60 days. The company posted a positive earnings surprise in two of the four trailing quarters with an average beat of 10.14%.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>